Skip to main content

Table 2 Baseline characteristics of patients with eGFR < 30 or dialysis who received levosimendan versus dobutamine alone

From: Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study

Variable

 

Before PSM‡

After PSM‡

Valid N

Levosimendan

(n = 52)

Dobutamine

(n = 374)

STD

Levosimendan

(n = 43)

Dobutamine

(n = 81)

STD

Age, year*

426

72.6 ± 12.1

70.4 ± 11.9

0.18

72.6 ± 11.6

71.3 ± 11.3

0.11

Male*

426

31 (59.6)

237 (63.4)

− 0.08

23 (53.5)

51 (63.0)

− 0.19

LVEF, %*

426

25.9 ± 7.4

29.6 ± 7.1

− 0.51

26.4 ± 7.5

25.6 ± 8.1

0.10

eGFR, mL/min/1.73m2*

279

18.8 ± 6.7

19.1 ± 6.7

0.08

18.3 ± 6.6

21.1 ± 6.1

− 0.43

Prior dialysis*

426

18 (34.6)

129 (34.5)

0.00

15 (34.9)

30 (37.0)

− 0.04

Inotropic agents during the index admission

 Dopamine*

426

14 (26.9)

51 (13.6)

0.34

10 (23.3)

19 (23.5)

 < 0.01

 Norepinephrine*

426

10 (19.2)

77 (20.6)

− 0.03

9 (20.9)

18 (22.2)

− 0.03

 Epinephrine*

426

5 (9.6)

59 (15.8)

− 0.19

4 (9.3)

9 (11.1)

− 0.06

AMI during the index admission*

426

16 (30.8)

85 (22.7)

0.18

14 (32.6)

22 (27.2)

0.12

PCI during the index admission*

426

11 (21.2)

36 (9.6)

0.32

9 (20.9)

16 (19.8)

0.03

Myocarditis during the index admission*

426

3 (5.8)

2 (0.5)

0.30

1 (2.3)

1 (1.2)

0.08

Mechanical ventilator*

426

36 (69.2)

151 (40.4)

0.61

27 (62.8)

46 (56.8)

0.12

IABP*

426

13 (25.0)

26 (7.0)

0.51

7 (16.3)

15 (18.5)

− 0.06

ICU days

426

11 [4, 18]

3 [0, 10]

NA

11 [4, 21]

5 [0, 13]

NA

Admission days

426

29 [15.5, 49]

24 [13, 42]

NA

29 [16, 53]

25 [13, 39]

NA

Risk score*

 SOFA

426

8.4 ± 2.1

8.9 ± 2.4

− 0.21

8.6 ± 2.2

8.6 ± 2.0

− 0.04

 APACHE III

426

50.2 ± 13.3

49.8 ± 15.4

0.03

50.9 ± 13.8

49.4 ± 13.5

0.11

Comorbidities

 Atrial fibrillation

426

16 (30.8)

145 (38.8)

− 0.17

15 (34.9)

24 (29.6)

0.11

 Diabetes mellitus

426

35 (67.3)

249 (66.6)

0.02

29 (67.4)

52 (64.2)

0.07

 Hypertension

426

43 (82.7)

311 (83.2)

− 0.01

35 (81.4)

63 (77.8)

0.09

 Dyslipidemia

426

35 (67.3)

223 (59.6)

0.16

28 (65.1)

57 (70.4)

− 0.11

Baseline medications

 Aspirin

426

43 (82.7)

250 (66.8)

0.37

35 (81.4)

61 (75.3)

0.15

 Clopidogrel

426

35 (67.3)

214 (57.2)

0.21

28 (65.1)

44 (54.3)

0.22

 Ticagrelor

426

18 (34.6)

72 (19.3)

0.35

12 (27.9)

22 (27.2)

0.02

 Beta-blockers

426

46 (88.5)

325 (86.9)

0.05

38 (88.4)

67 (82.7)

0.16

 ACE inhibitors

426

30 (57.7)

163 (43.6)

0.29

23 (53.5)

35 (43.2)

0.21

 ARB

426

37 (71.2)

235 (62.8)

0.18

29 (67.4)

53 (65.4)

0.04

 MRA

426

34 (65.4)

196 (52.4)

0.27

31 (72.1)

39 (48.1)

0.50

 Digoxin

426

20 (38.5)

153 (40.9)

− 0.05

20 (46.5)

29 (35.8)

0.22

 Amiodarone

426

30 (57.7)

188 (50.3)

0.15

27 (62.8)

33 (40.7)

0.45

 Ivabradine

426

28 (53.8)

84 (22.5)

0.68

22 (51.2)

23 (28.4)

0.48

Baseline laboratory data

 Hemoglobin, g/dl

425

11.3 ± 2.7

10.0 ± 2.0

0.55

11.1 ± 2.7

10.5 ± 2.2

0.27

 ALT, U/L

376

28 [15, 130]

23 [15, 45]

NA

35 [16, 130]

29 [16, 70]

NA

 BNP, pg/mL

271

4634

[1625, 5000]

2412

[1231.9, 4700]

NA

4634

[1625, 5000]

3030

[1580, 4700]

NA

 HCO3, mmol/L

261

21.1 ± 6.0

23.0 ± 5.8

− 0.31

21.2 ± 6.3

21.6 ± 5.0

− 0.08

 Total bilirubin, mg/dL

288

1.6 ± 2.0

1.5 ± 2.1

0.05

1.6 ± 2.1

1.5 ± 2.0

0.06

 BUN, mg/dL

419

66.7 ± 37.0

70.3 ± 38.6

− 0.10

70.6 ± 38.0

68.0 ± 36.7

0.07

 Sodium, mg/dL

426

139.2 ± 6.5

139.2 ± 6.3

0.00

140.0 ± 6.8

139.4 ± 6.7

0.09

 Potassium, mg/dL

426

4.2 ± 0.8

4.1 ± 0.7

0.06

4.3 ± 0.7

4.1 ± 0.7

0.17

 Platelet, 1000/μL

424

163.7 ± 71.9

169.1 ± 85.4

− 0.07

166.3 ± 75.3

183.3 ± 92.1

− 0.20

 Hematocrit, %

425

34.1 ± 7.6

30.7 ± 5.9

0.51

34.0 ± 7.6

32.1 ± 6.5

0.28

 WBC, 1000/μL

424

9.9 ± 3.9

10.1 ± 5.5

− 0.04

10.4 ± 3.9

10.6 ± 5.0

− 0.05

 Albumin, mg/dL

328

3.2 ± 0.5

3.1 ± 0.5

0.05

3.1 ± 0.5

3.2 ± 0.5

− 0.11

 Lactate, mg/dL

184

29.9 ± 34.1

32.9 ± 32.5

− 0.09

30.5 ± 36.2

41.5 ± 39.9

− 0.29

 INR

319

1.7 ± 1.0

1.6 ± 0.8

0.17

1.8 ± 1.0

1.5 ± 0.8

0.34

  1. PSM propensity score matching, STD standard difference, LVEF left ventricular ejection fraction, eGFR estimated glomerular filtration rate, AMI acute myocardial infarction, PCI percutaneous coronary intervention, IABP intra-aortic balloon pumping, ICU intensive care unit, SOFA Sequential Organ Failure Assessment, APACHE Acute Physiology and Chronic Health Evaluation, ACEi angiotensin-converting enzyme inhibitor, ARBs angiotensin II receptor blockers, MRA mineralocorticoid receptor antagonist, ALT alanine aminotransferase, BNP B-type natriuretic peptide, BUN blood urea nitrogen, NA not available, WBC white blood count, INR international normalized ratio
  2. Data were presented as number (%), mean ± standard deviation or median [25th, 75th percentile];
  3. *Included in the calculation of propensity score